ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for alerts Register for real-time alerts, custom portfolio, and market movers

FAB Fusion Antibodies Plc

3.75
-0.05 (-1.32%)
31 May 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type Share ISIN Share Description
Fusion Antibodies Plc LSE:FAB London Ordinary Share GB00BDQZGK16 ORD 4P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  -0.05 -1.32% 3.75 3.70 3.80 3.80 3.75 3.80 474,407 11:29:57
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
Pharmaceutical Preparations 2.9M -2.6M -0.0272 -1.38 3.58M
Fusion Antibodies Plc is listed in the Pharmaceutical Preparations sector of the London Stock Exchange with ticker FAB. The last closing price for Fusion Antibodies was 3.80p. Over the last year, Fusion Antibodies shares have traded in a share price range of 3.10p to 9.875p.

Fusion Antibodies currently has 95,365,564 shares in issue. The market capitalisation of Fusion Antibodies is £3.58 million. Fusion Antibodies has a price to earnings ratio (PE ratio) of -1.38.

Fusion Antibodies Share Discussion Threads

Showing 276 to 300 of 4100 messages
Chat Pages: Latest  20  19  18  17  16  15  14  13  12  11  10  9  Older
DateSubjectAuthorDiscuss
12/8/2020
09:13
Being from NI it pains me to say I had to sell these
volsung
11/8/2020
09:57
Funding nothing to do with preferential treatment.. it's the education system and especially Queens highly developed IT and Tech sector. Look at the large number of tech companies in NI, all doing very well eg Kainos for one.
xtomo
11/8/2020
09:51
Seems like a strange thing to RNS, am I missing something GLA
mickluv1
11/8/2020
09:48
A bit of news this morning. NI certainly seem to do well with this sort of funding, presumably as a result of Theresa May's generosity towards the region to ensure Arlene's support a few years ago
timbo003
11/8/2020
09:28
2.5% Down on a 400 sell really!!!!
mickluv1
08/8/2020
18:52
Last time the chart mirrored this pattern back in April it shot up above 2 pound
fund1
07/8/2020
21:35
It’s a gamble but they have produced 150 plus different antibodies for big pharma some of which are on trials, some phase 2, revenue interest carry on some.

I see no reason why Fusion can’t produce and humanise the antibodies needed to treats patients.

A chance for Fab to showcase their tech and platforms.

Just a case of waiting to see what happens.

Time will tell.

superg1
07/8/2020
15:26
There seems several large holders and very few shares to trade, so every sell or buy will make this share go up or down. Let's see what next week will bring to the table, it's good that we don't have many derampers or rampers, this will do the job it's self
amrishbhim
07/8/2020
15:22
I truly believe there something that's happening or has happened and news will follow soon, I can say at least there no bad news for additional money but more to additional contracts.
amrishbhim
07/8/2020
15:19
That would be fantastic, I feel like something is about to happen GLA
mickluv1
07/8/2020
15:16
No rampingI assure you, I have a feeling we going to hear more next week on several projects lined up and the COVID 19, let's see if we can see the numbers like SNG and TILS here.
amrishbhim
07/8/2020
14:47
Who are the ones pushing it up not finished buying yet
fund1
07/8/2020
14:14
Guess only takes a few buys or sells to move this one
nallen1
07/8/2020
13:02
Something happening?
nmulm
07/8/2020
10:10
The results last year were on Tuesday July 2nd, when I asked Anna (Walbrooke) last week about when the results will publish, she said they should be out within two weeks, so next week?

What I want to know is now many of the new projects they are undertaking for customers are they managing to negotiate a royalty or milestone in addition to the fee for service. I think this is probably critical for a medium term re-rating of the shares, although I suspect many investors eyes will just be scanning the results for the word COVID, which may drive the share price in the short term.

timbo003
06/8/2020
07:41
This reminds me of the terrible spread on TILS weeks before it became the latest hot stock. Don't let a big spread put you off buying if you have done the research you have to pay the price given.
whatsthepoint
05/8/2020
22:14
Anyone know when next news may be due? Just a small stake for now but might pick up more in the coming months
money4me
05/8/2020
19:55
I think the market makers know that there are a lot of long term holders who have no intention of selling...😉
woodpeckers
05/8/2020
15:51
Been monitoring this for a few weeks, however, that spread is outrageous.
lako42
04/8/2020
22:45
Yanks going down the MAB route looking for an effective treatment for Covid-reckon authorities the world over looking beyond vaccines which may or may not work. But MABs could be the way forward in managing a lot of the more obstreperous infectious diseases. Something here for Fab's library maybe?


hxxps://investor.lilly.com/news-releases/news-release-details/lilly-begins-worlds-first-study-potential-covid-19-antibody

cumnor
03/8/2020
17:18
Yes any good news and it's at least a bagger here. Still been adding bits here and there will stop at my next big purchase or a massive rise which ever comes first
fund1
03/8/2020
16:56
It's interesting that a small premium was paid for the 10k this morning, with a little bit of buying pressure this should lift off. GLA
mickluv1
31/7/2020
22:33
Our turn coming soon. I have a little bit at the side incase of anymore dips
fund1
29/7/2020
18:27
I see the 7k buy pushed it up. I can't even imagine what real positive news will do to the price when there is a scramble for the shares if 7k can push it up 3 percent.
fund1
28/7/2020
13:08
Ignoring covid.

H1 report looked good with the library forecast them to start to kick in H1 2021 which is the period we are in now. Materials revenues to kick in forecast 2022 = 1st April 2021 on.

YE already suggested 79% up on last year.

Bio = big spending but not at Fab as its a service, and has had 8 of the top 10 biggest pharmacies companies so far as a client.

The recent covid plan is different they are doing that off their own bat and will market it. Parts of that like proteins going on offer now.

superg1
Chat Pages: Latest  20  19  18  17  16  15  14  13  12  11  10  9  Older